Genmab — November 2019

[Sukkeralf]

bibob - deadline for late breaker was in october

[Sukkeralf]

So at least not secret to the ASH commitee

[Bulder]

Only 6 abs will be selected.

[Bulder]

bibob, they not only "may", they must keep it as a secret, as data are embargoed until publication.

[Solsen]

Foreløbig ny ATH i dag med 1519 kr

[bibob]

Thx Bulder and Sukker.

[Sukkeralf]

Måske data fra dette studie:

[Sukkeralf]

(clinicaltrials.gov)

[Sukkeralf]

Næh ikke alligevel - der kommer en poster fra dette studie

[Solsen]

CD20/CD3 er vel stadig en mulighed ?

[E_L]

i doubt it as they already have an oral presentation? (which i am already happy with..)

[Solsen]

BCMA/CD3 is my guess then

[E_L]

I am gonna feel reallly guilty now if they don't get a late breaker after starting this

[Solsen]

I belive the BCMA/CD3 duobody could be highly effective in responses and together with Dara we could have a drug combi that could put Revlimid aside. Just dreaming perhaps.

[bibob]

dream further Solsen

[kkjoel]

Så er det i dag det sker..... det endelig brud væk fra gl. bund. Farvel 1500!

[kkjoel]

Hils 1600 i kølvandet om et par måneder

[bongobob]

I see you retracement and raise you a CD3xCD20 50:50 deal with Roche

[bibob]

Det er godt nok en ordentlig gang abstracts Genmab har på ASH. 37 stk. Og det er vel hovedparten som vi har nævnt som LB der er med, så chancen for en LB er jo nok ikke så stor.https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-be-presented-2019-ash-annual-meeting

[kkjoel]

Og AQR har mindsket deres shortpos. fra 1,09 til 0,99%. Hallelujah. Og må de brænde i helvede.. mere end nu. Gnæk!!